Study of BMS-986158 in Subjects With Select Advanced Cancers

Status:	Recruiting
Healthy:	No
Age Range:	12 - Any
Updated:	8/31/2018
Start Date:	June 5, 2015
End Date:	December 3, 2021
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email:	Clinical.Trials@bms.com

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and
pharmacodynamics of BMS-986158 in subjects with select advanced cancers

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Males and females 12 years old or older

- Must have select advanced cancers with specific genetic profiles

- Must have received appropriate standard of care

- At least one measurable lesion at baseline

- Expected to have life expectancy of at least 3 months

- Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria:

- Concomitant second malignancies

- Uncontrolled or significant cardiovascular disease

- Inadequate bone marrow function

- Chronic gastrointestinal illness

- Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

Institute for Translational Oncology Research (ITOR)

Greenville, South Carolina 29605

Phone: 864-679-3926

from

Greenville, SC